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fatty acids with circulating immune 
cells and serum biomarkers 
in patients with multiple sclerosis
Stephanie Trend1,2, Jonatan Leffler1, Anderson P. Jones1, Lilian Cha1, Shelley Gorman1, 
David A. Brown3, Samuel N. Breit4, Allan G. Kermode2,5, Martyn A. French6, 
Natalie C. Ward7,8 & Prue H. Hart1*
Altered composition of gut bacteria and changes to the production of their bioactive metabolites, the 
short‑chain fatty acids (SCFAs), have been implicated in the development of multiple sclerosis (MS). 
However, the immunomodulatory actions of SCFAs and intermediaries in their ability to influence MS 
pathogenesis are uncertain. In this study, levels of serum SCFAs were correlated with immune cell 
abundance and phenotype as well as with other relevant serum factors in blood samples taken at first 
presentation of Clinically Isolated Syndrome (CIS; an early form of MS) or MS and compared to healthy 
controls. There was a small but significant reduction in propionate levels in the serum of patients with 
CIS or MS compared with healthy controls. The frequencies of circulating T follicular regulatory cells 
and T follicular helper cells were significantly positively correlated with serum levels of propionate. 
Levels of butyrate associated positively with frequencies of IL‑10‑producing B‑cells and negatively 
with frequencies of class‑switched memory B‑cells. TNF production by polyclonally‑activated B‑cells 
correlated negatively with acetate levels. Levels of serum SCFAs associated with changes in circulating 
immune cells and biomarkers implicated in the development of MS.
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CIS  Clinically isolated syndrome
DN  Double negative  (IgD−CD27−)
GDF15  Growth differentiation factor 15
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MBC  Memory B-cells
MFI  Median fluorescence intensity
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Tfr  T follicular regulatory
Treg  T regulatory
25(OH)D  25-Hydroxy vitamin D
Multiple sclerosis (MS) is a complex inflammatory neurological disorder of unknown aetiology involving abnor-
malities in a range of immune cells, including T-cells and B-cells. The variety of immune cells implicated in the 
immunopathogenesis of MS raises the possibility that alongside expression of genetic risk  factors1, agents with 
immunomodulatory activity on immune cells may contribute to environmental risks for developing the disease.
The human microbiome is a major determinant of human health over the life course, providing a range of 
soluble factors that can contribute to regulation of the human immune system. Healthy people have a “core 
microbiome” composition which has been shown to be disturbed in several disease states. Studies investigating 
the gut microbiome in patients with MS have demonstrated evidence of dysbiosis (reviewed  in2,3). However, 
outcomes have been variable between studies, with mostly non-replicable findings of changes in the abundance 
of diverse groups of  bacteria4–8. Determining the clinical importance of changes in specific groups of microbes is 
therefore difficult to achieve. Examining downstream products of microbial metabolism might provide a species-
independent assessment of the immune modulating activities of the gut microbiome. Recently, the composition 
of the gut microbiome was investigated alongside metabolomics, revealing decreased levels of the short-chain 
fatty acids (SCFAs) butyrate and propionate in the gut of MS  patients9. In one study, the proportions of SCFA-
producers Roseburia, Coprococcus and Blautia were reduced by between 2- and fivefold in patients with  MS10. 
The proposal that the changes in gut microbiota in MS patients translate to changes in the SCFAs they produce 
have been supported by reports of lower serum levels of  butyrate10 and  propionate11 in the serum of MS patients.
The SCFAs acetate, propionate and butyrate, are the main metabolites produced in the human colon by bacte-
rial anaerobic fermentation of indigestible polysaccharides such as dietary fibres and resistant starch; very small 
amounts of SCFAs are also produced by colonic microbiota from amino acid metabolism (reviewed  in12). SCFAs 
are small organic monocarboxylic acids of up to six carbon atoms in length. These SCFAs may act locally in the 
gut, for example by maintaining the integrity of the intestinal epithelium, provision of energy for colonocytes 
and induction of regulatory  cells13,14. However, SCFAs may also act in distant tissues. Levels of SCFAs in stool 
do not necessarily predict levels of SCFAs in serum and distant lymphoid tissues because of differences in the 
structural integrity of the gut epithelium and/or the expression of receptors that mediate transport of SCFA across 
the colonocytes (reviewed  in12). An investigation of the circulating levels of SCFAs provides one mechanism to 
investigate the collective and indirect effects of the microbiome on distal immune cells.
Within the immune system, SCFAs are generally considered anti-inflammatory although their mechanisms of 
action require further  definition3,12,15. By binding to G-protein coupled receptors on immune  cells16, SCFAs may 
epigenetically regulate gene expression by inhibition of histone deacetylase activity and subsequent changes to 
lysines in nucleosomal  histones17–19. SCFAs may also control lipid metabolism and gluconeogenesis in immune 
cells; the survival and activity of immune cells are determined in large part by flux through such metabolic 
 pathways20.
In order to determine whether changes to levels of circulating SCFAs in patients with MS provide clues to 
drivers of their immune-mediated disease, levels of acetate, propionate and butyrate were measured in the serum 
of patients with clinically isolated syndrome (CIS) or MS and compared with the levels in sera from healthy 
controls. Of importance, the patients were therapy-naive and blood was collected as early as possible after their 
presentation of CIS or MS. We hypothesised that the putative immunoregulatory activities of the SCFAs would 
be associated with changes to the frequencies and functions of circulating immune cells including the ratios 
of effector to regulatory cells and other disease biomarkers in blood. The levels of the SCFAs were compared 
with the frequencies of, and cytokine production by, T- and B-cell subpopulations, and with levels of mRNA for 
tryptophan and arginine catabolic enzymes that regulate proliferation and metabolic activity of immune cells. 
The levels of the SCFAs were also compared with those of serum biomarkers that we, or others, have implicated 
in MS development and progression. These included  IgG321,22 and 25-hydroxy vitamin D (25(OH)D)23. In addi-
tion, serum levels of growth differentiation factor 15 (GDF15) were assessed as this factor has recently shown to 
be increased in patients with  MS24. Frequently referred to as a stress responsive cytokine that increases during 
tissue injury and inflammation, the production by GDF15 by adipocytes, cardiomyocytes and macrophages 
may be related to the metabolic processes associated with SCFA  function25. This study aimed to investigate the 
relationship between circulating SCFAs and MS development in our therapy-naive cohort.
Results
SCFA levels in the serum of patients with CIS or MS and association with clinical out‑
comes. Serum levels of butyrate, acetate and propionate were assessed in CIS/MS patients and compared to 
those in healthy controls. A small but significant difference was observed for propionate levels between controls 
and CIS/MS patients (Fig. 1). There was a subset of CIS/MS patients with relatively low serum butyrate or acetate 
levels, but the levels in the CIS/MS patient group were not significantly different from controls (Fig. 1). There 
were no associations between levels of any SCFA and the time since their MRI when presenting with CIS or MS 
(n = 30, data not shown). Serum levels of SCFAs from the CIS patients did not predict the time from their diag-
nosis with CIS and their conversion to MS by appearance of new lesions on their MRI consistent with conversion 
to MS (n = 16, data not shown).
Association of SCFAs with the prevalence and function of peripheral blood T‑ and B‑cell sub‑
sets from CIS/MS patients. This laboratory has analysed both the prevalence and function of circulating 
B- and T-cells of therapy-naive patients recently presenting with CIS or  MS26–29. Due to the variable numbers of 
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samples that had been available at the time of each assessment, there was some minor variation in the sample 
numbers between analyses (as indicated).
Serum SCFA levels and the frequency of T‑cell subsets and their function. In the blood from 20 patients with 
CIS and 5 patients with MS, this laboratory has measured the prevalence of  CD4+ T-cell  subsets26. PBMCs from 
11 of these 25 patients were cultured with phorbol myristate acetate and ionomycin for 4 h in the presence of 
Brefeldin A, and the intracellular production of the cytokines IL-17, IFNγ and IL-10 measured in  CD4+ T-cells26.
There was no correlation between the levels of serum SCFAs and the prevalence of  CD3+ cells,  CD4+ cells, 
 CD8+ cells measured as a percentage of PBMC (data not shown). The frequencies of  FoxP3+CXCR5− T regulatory 
cells (Tregs; %CD4+ T-cells) were not correlated with serum SCFA levels (Fig. 2a–c). In contrast, the frequen-
cies of T follicular helper cells (Tfh)  (CD4+CXCR5+) correlated positively with both serum butyrate and serum 
propionate levels (Fig. 2d–f).
FoxP3+CXCR5+ T follicular regulatory cells (Tfr; %CD4+ T-cells) were also examined: Tfr counteract the 
functions of Tfh by downregulating the production of effector cytokines such as IL-4, IFNγ and IL-21 that are 
essential for B-cell activation and class switch  recombination30–32. In our CIS/MS cohort (n = 25), the frequency 
of Tfr correlated with levels of propionate, but not other SCFAs in serum (Fig. 2g–i). In addition, propionate 
levels significantly negatively correlated with the relative ratio of Treg:Tfr (rho -0.43; p = 0.03). For butyrate and 
Figure 1.  SCFA levels in serum from controls (n = 10), and patients with CIS or MS (CIS/MS; n = 30). (a) 
Butyrate, (b) acetate, and (c) propionate levels. Bars show median and interquartile range. Comparisons were 
made using non-parametric tests (Mann–Whitney tests for two comparisons).
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Figure 2.  Correlations between serum SCFA levels in patients with CIS/MS and  CD4+ T cell subsets. Top panel 
shows T regulatory cells (Treg;  CD4+Foxp3+CXCR5−; n = 25), middle panel shows T follicular helper cells (Tfh; 
 CD4+CXCR5+; n = 23), bottom panel shows T follicular regulatory cells (Tfr;  CD4+Foxp3+CXCR5 + ; n = 25), 
and their correlation with (a,d,g) butyrate, (b,e,h) acetate and (c,f,i) propionate levels in serum. Statistical 
comparisons were made with nonparametric Spearman’s correlation; rho values and p values are shown. Linear 
regression line is shown for illustrative purposes only. Statistically significant p values are shown in bolded font.
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acetate, there was no significant correlation with the Treg:Tfr ratio (rho = 0.08, p = 0.7 and rho = 0.02, p = 0.9, 
respectively). There was no correlation between serum acetate, propionate or butyrate levels and the ratio of 
Tfh:Tfr (n = 23; rho = − 0.07, p = 0.74; rho = − 0.1, p = 0.64; rho = 0.05, p = 0.82, respectively).
No correlation was found between serum SCFA levels and Th1 or Th17 cell frequencies (%CD4+ T-cells) 
(n = 25 CIS/MS) or expression of IL-10, IFNγ or IL-17 in total  CD4+ T-cells (n = 11 CIS/MS) (data not shown).
In summary, a relationship was demonstrated between serum levels of some SCFAs and the frequencies of 
circulating follicular T-cells (Tfh or Tfr cells) but not the frequency or cytokine production of other subpopula-
tions of  CD4+ T-cells.
Serum SCFA levels and the frequency of B‑cell subsets and their function. In the blood from 21 patients with 
CIS/MS, the frequencies of eight CD19/CD20+ B-cell subsets were previously  measured29. We have also cultured 
PBMCs from these patients for 18 h and measured the intracellular production of the prototypical pro- and anti-
inflammatory cytokines TNF and IL-10 in B-cell subsets, both in the absence and presence of R848, a polyclonal 
stimulator of B-cells through the TLR7  receptor29.
The frequencies of total B-cells (% PBMC) correlated positively with serum levels of butyrate for CIS/MS 
patients (n = 21; Fig. 3a). Similarly, naive B-cell frequencies (% B-cells) appeared positively correlated with serum 
butyrate but this was not statistically significant (p = 0.06; Fig. 3b). In contrast, frequencies of class-switched 
MBCs (%B-cells) were significantly negatively correlated with butyrate levels (p = 0.03; Fig. 3c). No other cor-
relations were observed between serum SCFA levels and frequencies of B-cell subsets (naive, transitional,  IgMhi 
MZ-like B-cells,  IgMlo MZ-like B-cells, IgM-only MBC,  IgM+ double negative  (IgD−CD27−; DN),  IgM− DN, and 
plasmablasts as %B-cells) (data not shown).
When PBMCs were cultured for 18 h in the absence of exogenous stimulation and the frequency of IL-
10-expressing B-cells compared with levels of SCFAs, the percentage of both naïve and  IgMhi MZ-like B-cells 
that expressed IL-10 correlated positively with the concentration of butyrate in serum samples from patients 
with CIS/MS (Fig. 4a,e). There was no significant correlation of SCFAs with IL-10 production by the other 
B-cell subsets. The median fluorescence intensity (MFI) for IL-10 in unstimulated naive B-cells but not other 
B-cell subsets, also correlated with serum butyrate levels (Fig. 4c,g). In R848-stimulated B-cells, the frequency 
of naive B-cells, but not  IgMhi MZ-like B-cells, expressing IL-10 correlated with serum butyrate levels (Fig. 4b,f). 
Upon R848-stimulation, the MFI of IL-10 in  IgM+ DN B-cells correlated significantly with serum butyrate levels 
(Fig. 4h) and was close to significant in naïve B-cells (Fig. 4d).
When serum SCFA levels were tested for association with TNF production by B-cell subsets, acetate negatively 
correlated with  TNF+  IgMhi MZ-like B-cell frequencies in R848-stimulated but not unstimulated cells (Fig. 5a,b). 
In addition, the expression of TNF (MFI) by both the  IgMhi MZ-like B-cells and IgM-only MBC correlated 
negatively with serum acetate levels for R848-stimulated samples (Fig. 5c–f).
In summary, serum butyrate levels significantly associated with IL-10 expression in some unstimulated and 
R848-stimulated  IgM+ B cell subsets, and serum acetate was negatively associated with the capacity of some 
stimulated  IgM+ B cell subsets to produce TNF.
Associations of serum SCFA levels with tryptophan and arginine catabolic enzyme mRNA 
expression in PBMC. We have previously published that levels of mRNA for indoleamine 2,3-dioxygenase 
(IDO)1/2 and arginase (ARG)1/2 are increased in PBMCs from CIS/MS  patients33 and might provide a sustained 
homeostatic mechanism to control MS-associated inflammation. Expression of these enzymes in PBMCs from 
25 CIS/MS patients was compared with serum SCFA levels, since butyrate has been reported to increase IDO1 
expression in dendritic cells in culture and their ability to promote Treg  differentiation34. IDO1 mRNA levels 
correlated positively with serum acetate levels, and ARG1 levels with serum butyrate (Fig. 6a-d). However, IDO1 
and IDO2 mRNA levels did not correlate significantly with butyrate levels (p = 0.1 and p = 0.08, respectively).
Associations of serum SCFA levels with other disease biomarkers in serum from CIS or MS 
patients. Other disease biomarkers potentially involved in MS development and whose levels may associate 
with SCFA levels were examined in aliquots of serum from patients with CIS/MS.
Serum levels of GDF15 have been reported to be increased in MS  patients24 and were also higher in patients 
with CIS/MS (n = 30) in our study although the difference from healthy controls (n = 10) was not statistically 
different (p = 0.057) (Fig. 7a). Serum levels of GDF15 positively correlated with serum levels of both acetate 
and butyrate in samples from the CIS/MS patients. A similar trend toward correlation between propionate and 
GDF15 was not significant (p = 0.08) (Fig. 7b–d).
Given that associations between the frequencies of class-switched MBC and serum butyrate were detected 
(Fig. 3c) and higher  IgG3 levels associate with CIS to MS  conversion21, associations were investigated between lev-
els of SCFA and different immunoglobulins. No correlation was detected between SCFA concentrations and levels 
of IgG, IgM, IgA, or  IgG2-4, or their proportions as a percentage of total IgG (n = 28 CIS/MS) (data not shown). 
In addition, serum B-cell activating factor (BAFF) which is associated with B-cell survival and is increased in 
serum from patients with  MS35, was investigated, particularly as we detected increased frequencies of B-cells 
(%PBMC) in association with serum butyrate (Fig. 3a). However, There was no significant correlation between 
levels of SCFAs and serum BAFF (n = 20 CIS) although a trend toward a negative correlation between BAFF and 
acetate was observed (rho = − 0.39, p = 0.09) (data not shown).
There was no significant correlation between serum levels of SCFAs and 25(OH)D (n = 28 CIS/MS)(data not 
shown), the latter being a molecule frequently implicated in MS development if levels are  deficient23.
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Discussion
In this study of SCFAs in the serum of CIS/MS patients, propionate levels were significantly lower than those 
measured in the serum of healthy controls. Furthermore, several CIS/MS patients had butyrate and acetate 
levels that were below the range of levels measured in the serum from the healthy controls. The spread of levels 
of SCFAs may reflect the heterogeneity of the CIS/MS cohort but we were not able to associate lower levels with 
a clinical outcome. We aimed to determine whether associations of SCFAs with cells and mediators in the same 
blood sample taken soon after disease presentation may give clues to putative gut microbiota/SCFA involvement 
in MS pathogenesis, particularly by regulation of immunometabolic processes. Many correlations were detected 
between levels of SCFAs and circulating immune cells and their products, that suggested an unconfirmed poten-
tial of SCFAs to support T follicular cells and IL-10-expressing, less-differentiated B-cells, and to inhibit B-cell 
class switching and B-cell TNF expression. Overall, our results reflect a broad association of different SCFAs 
with immune cells that may contribute to regulation of both adaptive (T- and B-cell) and innate (myeloid cell) 
immune responses.
Figure 3.  Correlations between serum butyrate levels and B cell frequencies in (a) total B cells (% PBMC), 
(b) naive B cells (% B cells) and (c) class switched memory B cells (Sw-MBC; % B cells). Data are from PBMC 
isolated from 21 CIS/MS patients. Correlation was tested using nonparametric Spearman correlation; rho and p 
values are shown. Line of regression is shown for illustrative purposes only. Statistically significant p values are 
shown in bolded font.
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A significant positive association was detected of propionate with CXCR5-expressing Tfh and Tfr. These cells 
are associated with germinal centre reactions in secondary lymphoid organs as CXCR5 expression enables cell 
migration into germinal  centres36,37. Propionate levels significantly positively correlated with the frequency of 
Tfr but not Treg cells; this result suggests the effects of decreased propionate in patients with CIS/MS may be 
more important for circulating Tfr than Treg. In MS, fewer circulating functional Tfr have been implicated in the 
emergence of autoreactive B-cells, breakdown of self-tolerance and the emergence of ectopic germinal centre-
like structures within the  meninges38. In mouse models, butyrate and propionate supplementation have induced 
maturation of Tfr from Tregs via histone acetylation in Tfr marker  genes39. Therefore, lower propionate levels in 
the serum from CIS/MS patients could result in decreased regulation of germinal centre activity.
Lower levels of propionate and/or butyrate in the serum of MS  patients10,11 have been previously reported to 
associate with lower frequencies of Treg. In addition, Treg differentiation in the presence of these SCFAs has been 
observed in  culture10,11,40. However, in these previous studies, Treg cells were defined as  CD4+CD25+FoxP3+ but 
staining for CXCR5 was not performed. Thus, Treg and Tfr populations were not separately analysed; we have 
published that Tfr represent approximately 24% of total  CD4+CD25+Foxp3+ cells in both healthy controls and 
CIS  patients26. In our study, Treg cells were defined as  CD4+FoxP3+CXCR5− and no associations with SCFAs 
were demonstrated in the CIS/MS cohort. Tfr originate from  CXCR5−FoxP3+ thymic-derived Treg through 
dendritic cell priming (reviewed  in41); in vitro studies are required to determine how propionate may regulate 
the differentiation of human Tfr from Treg.
The success of anti-CD20  therapies42 has highlighted the importance of B-cells in the immunopathogenesis 
of MS. Associations between B-cells and SCFAs were frequent. Levels of serum butyrate positively correlated 
with the frequency of total B-cells (as% PBMCs) and naive B-cells (as% B-cells). Butyrate levels also negatively 
associated with the proportion of class-switched MBC. These results suggest that butyrate might affect B-cell 
differentiation in humans, a proposition that is supported by a report that butyrate and propionate fed to mice 
can reduce B-cell class-switching and plasma cell  differentiation43. This effect of butyrate may be complemented 
by propionate stimulating the number of Tfr. Butyrate levels also associated positively with both endogenous 
and TLR7-induced IL-10 production by several  IgM+ B-cells subsets. Lower levels of serum acetate associated 
with increased production of TNF by B-cell subsets. Thus, lower butyrate and acetate levels may induce B-cell 
subsets to be more inflammatory with decreased IL-10 and increased TNF production; outcomes supported by 
the ability of SCFAs to epigenetically edit the transcription of cytokine  genes18,43,44. An indirect effect of butyrate 
on B-cells may involve the microbial metabolism of tryptophan, causing the activation of the aryl-hydrocarbon 
receptor on B-cells and promoting their differentiation to B-cells with regulatory  potential45.
Serum levels of acetate also positively correlated with PBMC mRNA levels of the tryptophan catabolic 
enzyme, IDO-1. Butyrate positively correlated with ARG-1 mRNA levels, an arginine catabolic enzyme prin-
cipally expressed by macrophages. Both enzymes reduce amino acids for activation and expansion of immune 
cells and allow production of downstream immunomodulatory  metabolites46. Levels of serum GDF15 correlated 
positively with serum butyrate and acetate levels and a similar trend was observed for propionate (p = 0.08). 
The involvement of GDF15 in MS pathogenesis requires further study. However, GDF15 is neurotrophic and 
in a model of CNS injury, transgenic overexpression of GDF15 benefited injury resolution by modifying the 
peripheral immune  response47. This study suggests that levels of serum GDF15 may be inter-related with SCFA-
producing gut microbiota. Vitamin D determined principally by exposure of skin to UV  radiation48 may alter 
the gut microbiome and in turn, SCFA levels. However, serum levels of 25(OH)D showed no correlation with 
SCFAs (data not shown).
The strength of our report is that to our knowledge, such a thorough analysis of associations of SCFA levels 
with immune cells and serum disease biomarkers has not previously been performed. In previous studies of 
serum SCFA associations with MS, patients generally lived in the northern hemisphere and at higher latitudes. 
This study was performed in Perth, Australia  (32oS), where the local diet of the patients may have differed for 
seasonal, cultural and geographical reasons. It is important that in our study, like that of Duscha and colleagues 
in  Germany11, lower levels of propionate were detected in the serum of CIS/MS patients. As MS is likely initi-
ated by peripherally-activated, autoreactive lymphocytes that can then cross the blood–brain barrier (reviewed 
 in49), our study is relevant as serum SCFAs were analysed against circulating immune cells and mediators that 
subsequently may, upon entry into the central nervous system, be potential drivers of myelin-degrading cells.
The limitations of the study include our inability to determine whether the associations reported are also 
relevant to a control population. There was power to examine SCFA associations with the frequencies of cells and 
mediators only in samples from the CIS/MS patients. Further associations particularly for T-cell subsets may be 
detected with larger numbers of patients. Our analyses could not determine the direction of the communica-
tion between the circulating immune cells and biomarkers, and the gut microbiota. The communication is most 
likely bidirectional, whereby SCFAs affect not only immune processes but also, immune cells and their mediators 
regulate the gut microbiota. For example, it has recently been reported that arginase can alter the  microbiome50. 
In addition, the gut microbiome can be considered a hub for integrating signals from the immune and other body 
 systems51. Our correlative studies could not determine whether there may be redundant, additive or synergistic 
actions of the SCFAs on immune cells. Also, the site of interaction of SCFAs with developing immune cells that 
allow associations to be detected in the blood, could not be determined and may reflect initiation at the gut wall, 
in the bone marrow, or in secondary lymphoid organs. However, the associations observed in this study align 
with findings from experimental studies supporting a potential ability of SCFAs to regulate immune cells and 
their function in MS. The clinical outcomes investigated were very limited so any prognostic value of reduced 
SCFA concentrations would be premature.
To conclude, the measurement of SCFAs in the serum of patients with CIS/MS provided a window to dis-
sect potential mechanisms of gut-brain communication that may be associated with MS development, and to 
pinpoint the immune cells and mediators that may be intermediates in that pathway. Although only associative, 
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this study adds supportive data to emerging proposals that changes in diets for MS patients could increase the 
production of beneficial SCFAs via changes to the microbiome, or MS patients be supplemented with particular 
SCFAs or pre/probiotics to improve clinical  outcomes11,52,53. In our study, SCFA levels were associated principally 
with processes reflecting the function of germinal centres and IL-10-producing B-cells, rather than Treg cells. In 
serum from our CIS/MS cohort, propionate was significantly reduced compared with controls and highlights the 
functions of propionate on cells controlling germinal centre reactions (Tfh and Tfr) as a potentially important 
process in MS pathogenesis. Further studies of SCFAs and blood cells in vitro, and SCFA supplementation studies 
in vivo, will help to further define the mechanisms of action of SCFAs, and their possible association with factors 
determining the development and progression of MS.
Methods
Donors of PBMC and serum. Samples from patients with clinically isolated syndrome (CIS), the earliest 
form of MS (n = 20) were taken from the PhoCIS  trial54. Serum and cells from their baseline blood donation 
were analysed, which was taken within 120 days of their diagnosis of CIS by neurological history, examination, 
appropriate laboratory investigations and magnetic resonance imaging (MRI). All were non-smokers and of 
Caucasian ethnicity. Patients defined as MS (n = 10) were typically those with an acute clinical episode and were 
recruited based on a recent MRI showing demyelinating disease consistent with  MS21. From their MRI result, 
they were ineligible for recruitment for the PhoCIS trial. All CIS and MS patients were MS disease modifying 
therapy naïve and had not received steroids for > 30 days; they all had minimal disability due to the early nature 
of their disease (Expanded Disability Status Scale of < 3)54. In this study to increase the power of our analyses, the 
CIS and MS patients were considered as a single CIS/MS group (n = 30). Ten control age- and sex-matched indi-
viduals with no history of autoimmune disease were also recruited for serum donation. Details of the controls 
and CIS/MS patients are shown in Table 1. Donors of PBMC and serum were not fasting at time of venesection.
The study of the controls and CIS patients was approved by the Bellberry Human Research Ethics Commit-
tee (2014–02-082) and endorsed by the Human Research Ethics Office of the University of Western Australia 
(RA/4/1/6796). The study of the MS patients was reviewed and approved by the Sir Charles Gairdner Hospital 
Human Research Ethics committee (2006–073). All participants provided their written informed consent to 
participate. All experiments were performed in accordance with relevant named guidelines and regulations.
Serum and PBMC collection. Peripheral venous blood was collected into sodium heparin and SST vacu-
tainers (BD Biosciences, North Ryde, Australia) to isolate peripheral blood mononuclear cells (PBMC) and 
serum, respectively. Serum was following centrifugation at 800 × g for 10 min at room temperature and stored at 
-80 ºC until analyses. PBMC were separated from whole blood using a Lymphoprep (Axis-shield, Dundee, UK) 
gradient and cryopreserved as previously  described28.
SCFA measurement. As previously  described55, serum samples were spiked with 13C-sodium acetate, 
13C-sodium butyrate and 13C-sodium propionate (all from Sigma) as internal standards, acidified and homog-
enised in isopropanol. Following centrifugation, the supernatant was collected and injected into an Agilent HP 
6890 Series GC System, equipped with an Agilent 5973 Network Mass Selective Detector in splitless mode. Sam-
ples were separated on a DB Waxeter column (30 m × 0.25 mm × 0.25 μm), using a helium carrier gas at a flow 
rate of 1.0 mL/min. Identities and retention times of the SCFA were established using the volatile-free acid mix 
and were manually integrated using the MSD ChemStation (version D.03.00.611). Concentrations were deter-
mined using the internal standard references and calculated as nanomoles per microlitre of serum.
Assessment of T‑cell frequencies and cytokine production by flow cytometry. As previously 
described and graphically  shown26, T-cells  (CD3+) were identified using multicolour flow cytometry, includ-
ing T regulatory cells (Tregs;  CD4+FoxP3+CXCR5−), T follicular regulatory cells (Tfr;  CD4+FoxP3+CXCR5+), 
T follicular helper cells (Tfh;  CD4+FoxP3−CXCR5+), Th1 cells  (CD4+CXCR3+CCR6−) and Th17 cells 
 (CD4+CXCR3−CCR6+). The expression of intracellular cytokines IL-10, IFNγ and IL-17 in  CD4+ cells was exam-
ined in a subset of individuals with CIS (n = 11). Cytokines were examined in total PBMC using flow cytometry 
following a 4 h stimulation with phorbol 12-myristate 13-acetate and ionomycin in the presence of brefeldin A, 
as previously  described26.
Assessment of B‑cell frequencies and cytokine production by flow cytometry. B-cells were 
identified as CD19/CD20+ cells and subsets defined as previously described and  illustrated29,56,57 including tran-
sitional, naive marginal-zone (MZ)-like (both the  IgMhi and  IgMlo subpopulations), IgM-only memory B-cells 
(MBC), class-switched MBC (Sw MBC), and  IgM+ or  IgM− double negative B-cells. Intracellular IL-10 and TNF 
expression was examined in B-cell subsets cultured within PBMC for 18 h, with or without Resiquimod (R848), 
a TLR7/8 ligand, and in the presence of GolgiPlug, using flow cytometry as previously  described29. Cytokine 
Figure 4.  Correlations between serum butyrate levels and IL-10-producing B cells after PBMC culture for 
18 h (n = 21). Cells were cultured with or without Resiquimod (R848) as indicated. (a,b) The proportion of 
unstimulated or R848-stimulated naive B cells expressing IL-10 (%) and (c,d) the expression (MFI) of IL-10 in 
unstimulated or R848-stimulated naive B cells. (e–f) The proportion of  IgMhi MZ-like B cells expressing IL-10 in 
unstimulated or R848-stimulated cells. (g–h) The expression of IL-10 (MFI) in unstimulated or R848-stimulated 
 IgM+ DN B cells. Correlation was measured using nonparametric Spearman’s rho; statistically significant values 
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Figure 5.  Correlations between serum acetate levels and TNF-producing B cells after PBMC culture for 18 h (n = 21). Cells 
were cultured with or without Resiquimod (R848) as indicated. (a,b) The proportion of unstimulated or R848-stimulated 
 IgMhi MZ-like B cells expressing TNF (%) and (c,d) the expression (MFI) of TNF in unstimulated or R848-stimulated  IgMhi 
MZ-like B cells. (e,f) The expression of TNF (MFI) in IgM-only memory B cells in unstimulated or R848-stimulated cells. 
Correlation was measured using nonparametric Spearman’s rho; statistically significant values are shown in bolded font. Line 
of regression is shown for illustrative purposes only.
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expression by B-cell subsets was measured both as the proportion of positive cells (percentage of total B-cells) 
and the amount of cytokine expressed per cell (median fluorescence intensity (MFI)).
Measurement of IDO1/2 and ARG1/2 mRNA. As previously  published33, PBMCs were lysed, RNA was 
extracted and cDNA synthesis performed by standard techniques. Levels of mRNA for indoleamine 2,3-dioxy-
genase (IDO) 1 and IDO2, and arginase (ARG) 1 and ARG2 were determined by RT-PCR and relative gene 
expression determined.
Measurement of GDF15, BAFF, immunoglobulins and 25(OH)D. GDF15 and BAFF were measured 
using ELISA kits according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA). Total 
IgG,  IgG2–4, IgM, and IgA were measured as previously described, using bead-based commercial  immunoassays21. 
25(OH)D was measured in serum by LC–MS/MS as previously  published54.
Figure 6.  Correlations between serum levels of SCFA in patients with CIS/MS and PBMC mRNA for IDO 
and ARG (n = 25). (a) Correlation of IDO1 mRNA with acetate; (b) Correlation of ARG1 with butyrate; (c) 
Correlation of IDO1 mRNA with butyrate; and (d) Correlation of IDO2 mRNA with butyrate. Correlation was 
measured using nonparametric Spearman’s rho; statistically significant values are shown in bolded font. Line of 
regression is shown for illustrative purposes only.
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Statistical analyses. The data were not normally distributed according to Shapiro–Wilk normality tests, 
and therefore nonparametric data analyses were performed. Associations between continuous variables in 
patients with CIS or MS were compared in samples using Spearman rank-order correlation. Categorical com-
parisons were made using Fisher’s exact test. Comparisons of continuous outcomes between controls and those 
with CIS or MS were made using Mann–Whitney tests. P-values < 0.05 were considered statistically significant. 
Figure 7.  GDF15 levels in sera and correlations with SCFA levels. (a) GDF15 levels in serum from controls 
(n = 10) compared with those from patients with CIS/MS (n = 30). Correlation between GDF15 in serum from 
patients with CIS/MS and serum levels of (b) acetate, (c) butyrate, and (d) propionate. Correlation was analysed 
using nonparametric Spearman’s rho; p values < 0.05 were considered statistically significant and are shown in 
bolded font. Linear regression lines are shown for illustrative purposes only.
Table 1.  Demographic details of controls and patients with clinically isolated syndrome (CIS) or multiple 
sclerosis (MS). Statistical comparisons were made using a Mann–Whitney test for age and Fisher’s exact test for 
sex.
Controls (n = 10) CIS/MS (n = 30) p-value
Age (years; median, (interquartile range)) 35.4 (26.8–42.8) 34.5 (29.8–45.2) 0.4
Sex (female; n (%)) 8 (80%) 19 (63.3%) 0.29
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Analyses were performed using SPSS (IBM software v25, Armonk, USA) and Prism software (v8.2.0, GraphPad, 
San Diego, USA). In figures showing correlation of continuous variables, statistics from Spearman correlation 
are shown. A line of linear regression has been inserted into figures for illustrative purposes, but no linear regres-
sion statistics were included at any point in the analyses due to the nonparametric distribution of the dataset.
Data availability
The datasets analysed during the current study are available from the corresponding author on reasonable request.
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